Importantly, the molecular docking study further confirmed that afimetoran binds strongly to both mutant and wild type TOLLIP protein, and afimetoran has been recently reported in clinical study of Cutaneous Lupus Erythematosus, as toll like receptor 7/8 (TLR7/8) antagonist [87]. This evidence concerns the gene TOLLIP and cutaneous lupus erythematosus.